Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 282.00
Bid: 284.00
Ask: 288.00
Change: 2.00 (0.71%)
Spread: 4.00 (1.408%)
Open: 278.00
High: 286.00
Low: 278.00
Prev. Close: 280.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2020 15:54

UK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks

UK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks

Read more
29 May 2020 17:06

UK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil

UK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil

Read more
17 Apr 2020 13:19

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Read more
3 Mar 2020 14:24

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Read more
25 Feb 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
12 Feb 2020 17:27

FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

By Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...

Read more
10 Feb 2020 07:36

Hutchison Chi-Med shares up on updated results from 'CALYPSO'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.

Read more
23 Jan 2020 15:06

Hutchison China Prices USD110 Million American Depositary Share Offer

Hutchison China Prices USD110 Million American Depositary Share Offer

Read more
22 Jan 2020 10:44

Hutchison China Plans USD110 Million American Depositary Share Offer

Hutchison China Plans USD110 Million American Depositary Share Offer

Read more
20 Jan 2020 16:00

Hutchison Chi-Med upbeat on progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.

Read more
20 Jan 2020 11:37

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Read more
13 Jan 2020 09:01

Hutchison China Starts Phase II Study For Cancer Treatment In China

Hutchison China Starts Phase II Study For Cancer Treatment In China

Read more
20 Dec 2019 15:48

Hutchison Chi-Med gets priority review for 'surufatinib' in China

(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.

Read more
20 Dec 2019 12:10

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Read more
28 Nov 2019 14:58

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.